LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery

Proteomics

Volumn 12, Issue 14, 2012, Pages 2238-2246

  Lin, Lin ^a   Huang, Zhenzhen ^a   Gao, Yao ^a   Chen, Yongjing ^a   Hang, Wei ^a   Xing, Jinchun ^b   Yan, Xiaomei ^a  

^a XIAMEN UNIVERSITY   (China)

^b Xiamen First Hospital   (China)

Author keywords

Biomarker; Bladder cancer; Diagnosis; Kidney cancer; Metabolic profiling; Technology

Indexed keywords

14' APO BETA CAROTENAL; AZAPROSTANOIC ACID; BIOLOGICAL MARKER; DOCOSATRIENOL; EICOSATRIENOL; GANGLIOSIDE GM3; GLYCEROPHOSPHORYLCHOLINE; RETINOL; SPHINGANINE; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CONTROLLED STUDY; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; KIDNEY CANCER; MASS SPECTROMETRY; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; UROGENITAL TRACT CANCER; UROGENITAL TRACT DISEASE;

CHROMATOGRAPHY, REVERSE-PHASE; HUMANS; KIDNEY NEOPLASMS; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84864573058     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201200016     Document Type: Article

References (33)

1. Cairns, P., Gene methylation and early detection of genitourinary cancer: the road ahead. Nat. Rev. Cancer 2007, 7, 531-543.
2. Parkin, D. M., Global cancer statistics in the year 2000. Lancet Oncol. 2001, 2, 533-543.
3. Issaq, H. J., Nativ, O., Waybright, T., Luke, B. et al., Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J. Urology 2008, 179, 2422-2426.
4. Siu, K. W. M., DeSouza, L. V., Scorilas, A., Romaschin, A. D. et al., Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J. Proteome Res. 2009, 8, 3797-3807.
5. Vrooman, O. P. J., Witjes, J. A., Urinary markers in bladder cancer. Eur. Urol. 2008, 53, 909-916.
6. Kim, K., Aronov, P., Zakharkin, S. O., Anderson, D. et al., Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol. Cell. Proteomics 2009, 8, 558-570.
7. Pasikanti, K. K., Esuvaranathan, K., Ho, P. C., Mahendran, R. et al., Noninvasive urinary metabonomic diagnosis of human bladder cancer. J. Proteome Res. 2010, 9, 2988-2995.
8. Schwamborn, K., Krieg, R. C., Grosse, J., Reulen, N. et al., Serum proteomic profiling in patients with bladder cancer. Eur. Urol. 2009, 56, 989-996.
9. Gao, H. C., Dong, B. J., Liu, X., Xuan, H. Q. et al., Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal. Chim. Acta 2008, 624, 269-277.
10. Nicholson, J. K., Lindon, J. C., Holmes, E., 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29, 1181-1189.
11. Spratlin, J. L., Serkova, N. J., Eckhardt, S. G., Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 2009, 15, 431-440.
12. Kind, T., Tolstikov, V., Fiehn, O., Weiss, R. H., A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal. Biochem. 2007, 363, 185-195.
13. Zira, A. N., Theocharis, S. E., Mitropoulos, D., Migdalis, V., et al., 1H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. J. Proteome Res. 2010, 9, 4038-4044.
14. Perroud, B., Lee, J., Valkova, N., Dhirapong, A. et al., Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol. Cancer 2006, 5, 1-17.
15. Cubbon, S., Antonio, C., Wilson, J., Thomas-Oates, J., Metabolomic applications of HILIC-LC-MS. Mass Spectrom. Rev. 2010, 29, 671-684.
16. Greene, F. L., Page, D. L., Fleming, I. D., Fritz, A. et al., AJCC Cancer Staging Manual, Springer, New York 2002.
17. Schiffer, E., Vlahou, A., Petrolekas, A., Stravodimos, K. et al., Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin. Cancer Res. 2009, 15, 4935-4943.
18. Lin, L., Huang, Z., Gao, Y., Yan, X. et al., LC-MS-based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. J. Proteome Res. 2010, 10, 1396-1405.
19. Poynard, T., Halfon, P., Castera, L., Munteanu, M. et al., Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin. Chem. 2007, 53, 1615-1622.
20. Zhao, X. J., Fritsche, J., Wang, J. S., Chen, J. et al., Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics 2010, 6, 362-374.
21. Jia, L. W., Chen, J., Yin, P. Y., Lu, X., et al., Serum metabonomics study of chronic renal failure by ultra performance liquid chromatography coupled with Q-TOF mass spectrometry. Metabolomics 2008, 4, 183-189.
22. Taylor, L. A., Arends, J., Hodina, A. K., Unger, C., et al., Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis. 2007, 6, 1-8.
23. Sullentrop, F., Moka, D., Neubauer, S., Haupt, G. et al., P-31 NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma. NMR Biomed. 2002, 15, 60-68.
24. Yin, P. Y., Wan, D. F., Zhao, C. X., Chen, J. et al., A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol. BioSyst. 2009, 5, 868-876.
25. Burke, S. E., Roth, D. M., Lefer, A. M., Antagonism of platelet aggregation by 13-azaprostanoic acid in acute myocardial ischemia and sudden death. Thromb. Res. 1983, 29, 473-488.
26. Jurasz, P., Alonso-Escolano, D., Radomski, M. W., Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Brit. J. Pharmacol. 2004, 143, 819-826.
27. Fidler, I. J., The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3, 453-458.
28. Wang, X. J., Li, N., Liu, B., Sun, H. Y. et al., A novel human phosphatidylethanolamine-binding protein resists tumor necrosis factor alpha-induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization. J. Biol. Chem. 2004, 279, 45855-45864.
29. Wang, X. J., Li, N., Li, H. Z., Liu, B. et al., Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to tumor necrosis factor-alpha-induced apoptosis and cell growth arrest. Clin. Cancer Res. 2005, 11, 7545-7553.
30. Yao, Y., Huang, C., Li, Z. F., Wang, A. Y. et al., Exogenous phosphatidylethanolamine induces apoptosis of human hepatoma HepG2 cells via the bcl-2/bax pathway. World J. Gastroentero. 2009, 15, 1751-1758.
31. Sizeland, P. C. B., Chambers, S. T., Lever, M., Bason, L. M., et al., Organic osmolytes in human and other mammalian kidneys. Kidney Int. 1993, 43, 448-453.
32. Burg, M. B., Coordinate regulation of organic osmolytes in renal cells. Kidney Int. 1996, 49, 1684-1685.
33. Zeng, G. C., Gao, L. Y., Birkle, S., Yu, R. K., Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production. Cancer Res. 2000, 60, 6670-6676.